STOCK TITAN

Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Vir Biotechnology announced that Chief Medical Officer Phil Pang, M.D., Ph.D., will present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Conference on October 13 at 9:30 a.m. PT / 12:30 p.m. ET. A live webcast will be available via the Investors section of the Vir website and will be archived for 30 days post-event.

Vir focuses on using advanced technologies to combat serious infectious diseases, with ongoing projects targeting COVID-19, hepatitis B, influenza A, and HIV.

Positive
  • None.
Negative
  • None.

SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference on Wednesday, Oct. 13, at 9:30 a.m. PT / 12:30 p.m. ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.

The Company has used, and intends to continue to use, the Investors page of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investors website, in addition to following the Company’s press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.


FAQ

When is Phil Pang presenting at the Hepatitis B Virus Conference for Vir Biotechnology?

Phil Pang will present on October 13, 2021, at 9:30 a.m. PT / 12:30 p.m. ET.

How can I watch the presentation by Vir Biotechnology at the H. C. Wainwright Conference?

The presentation can be watched live via the Investors section of the Vir website.

What is the focus of Vir Biotechnology's development pipeline?

Vir Biotechnology's pipeline includes projects targeting COVID-19, hepatitis B, influenza A, and HIV.

Where can I find more information about Vir Biotechnology?

More information can be found on the official Vir website at www.vir.bio.

What technology platforms does Vir Biotechnology utilize?

Vir employs four technology platforms designed to enhance the immune system for treating infectious diseases.

Vir Biotechnology, Inc.

NASDAQ:VIR

VIR Rankings

VIR Latest News

VIR Stock Data

1.79B
117.08M
11.9%
74.31%
4.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN FRANCISCO